ABSTRACT
Primary cutaneous lymphomas are defined as a heterogenic group of T- and B-cell non-Hodgkin lymphomas that present initially in the skin. Patients with primary cutaneous lymphomas are at a higher risk for developing complications in case of infection with the novel coronavirus severe acute respiratory syndrome coronavirus 2. The coronavirus disease 2019 (COVID-19) pandemic has affected the established diagnostic approach, staging, and therapeutic guidelines in patients with primary cutaneous lymphomas. In the light of the current global health crisis, management of primary cutaneous lymphomas needs to be adjusted. The key to achieving this is to balance the optimal control of the lymphoma, with a minimal increase of the personal risk for COVID-19 exposure and complications.
Subject(s)
COVID-19/epidemiology , Lymphoma, B-Cell/therapy , Lymphoma, T-Cell, Cutaneous/therapy , Skin Neoplasms/therapy , COVID-19/prevention & control , Humans , Lymphoma, B-Cell/classification , Lymphoma, B-Cell/diagnosis , Lymphoma, T-Cell, Cutaneous/classification , Lymphoma, T-Cell, Cutaneous/diagnosis , Risk Assessment , SARS-CoV-2 , Skin Neoplasms/classification , Skin Neoplasms/diagnosisSubject(s)
Antineoplastic Agents/administration & dosage , Dermatology/trends , Lymphoma, T-Cell, Cutaneous/drug therapy , Skin Neoplasms/drug therapy , Telemedicine/trends , Administration, Cutaneous , Biopsy , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control/standards , Dermatology/organization & administration , Dermatology/standards , Humans , Lymphoma, T-Cell, Cutaneous/diagnosis , Lymphoma, T-Cell, Cutaneous/pathology , Pandemics/prevention & control , Self Administration , Skin/diagnostic imaging , Skin/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Telemedicine/organization & administration , Telemedicine/standards , United States/epidemiologyABSTRACT
The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis.